Glucose-responsive insulin by molecular and physical design

Glucose-responsive insulin is a therapeutic that modulates its potency, concentration or dosing relative to a patient’s dynamic glucose concentration. This Perspective summarizes some of the recent accomplishments in this field as well as discussing new computational algorithms that may aid in the d...

Full description

Saved in:
Bibliographic Details
Published in:Nature chemistry 2017-09, Vol.9 (10), p.937-944
Main Authors: Bakh, Naveed A., Cortinas, Abel B., Weiss, Michael A., Langer, Robert S., Anderson, Daniel G., Gu, Zhen, Dutta, Sanjoy, Strano, Michael S.
Format: Article
Language:English
Subjects:
631/154/309/2144
631/61/338/469
Analytical Chemistry
Biochemistry
Chemistry
Chemistry/Food Science
Chemists
Diabetes mellitus
Glucose
Innovations
Inorganic Chemistry
Insulin
Mathematical models
Organic Chemistry
Pancreas
perspective
Physical Chemistry
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glucose-responsive insulin is a therapeutic that modulates its potency, concentration or dosing relative to a patient’s dynamic glucose concentration. This Perspective summarizes some of the recent accomplishments in this field as well as discussing new computational algorithms that may aid in the development of such therapeutics. The concept of a glucose-responsive insulin (GRI) has been a recent objective of diabetes technology. The idea behind the GRI is to create a therapeutic that modulates its potency, concentration or dosing relative to a patient's dynamic glucose concentration, thereby approximating aspects of a normally functioning pancreas. From the perspective of the medicinal chemist, the GRI is also important as a generalized model of a potentially new generation of therapeutics that adjust potency in response to a critical therapeutic marker. The aim of this Perspective is to highlight emerging concepts, including mathematical modelling and the molecular engineering of insulin itself and its potency, towards a viable GRI. We briefly outline some of the most important recent progress toward this goal and also provide a forward-looking viewpoint, which asks if there are new approaches that could spur innovation in this area as well as to encourage synthetic chemists and chemical engineers to address the challenges and promises offered by this therapeutic approach.
ISSN:1755-4330
1755-4349
DOI:10.1038/nchem.2857